Abstract
Tepotinib (Tepmetko (TM), Merck) is a MET tyrosine kinase inhibitor being developed for the treatment of solid tumours. In quarter three of 2019 tepot......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
